IGSF3

Across TCGA pan-cancer cohorts, IGSF3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IGSF3 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher IGSF3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated IGSF3 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, KICH, and DLBC are the cancer types where IGSF3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	II,III,IV	0.912	0.605	.016	16	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
SCLC	OS	Median	III,IV	0.055	0.640	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	.006	6	view →
UCEC	OS	Median	IV	0.277	0.605	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IGSF3–BLCA (DFS)

Open the BLCA breakdown →